Predicting progression in fibrosing interstitial lung disease
Prognostic Biomarker Development in Progressive Fibrosing Interstitial Lung Disease
This project uses blood protein patterns to help predict which people with fibrosing interstitial lung disease will get worse over time.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11251252 on NIH RePORTER |
What this research studies
From your perspective, researchers will analyze blood plasma proteins using advanced proteomics and machine‑learning to create a signature linked to short‑term lung decline and three‑year transplant‑free survival. They will validate promising protein markers in an independent patient cohort drawn from pulmonary fibrosis networks. The work also links blood findings with CT imaging and clinical data to improve prediction across different ILD types. The goal is to turn these findings into reliable biomarkers that could guide earlier treatment decisions for people with fibrosing ILD.
Who could benefit from this research
Good fit: People diagnosed with fibrosing interstitial lung disease who can provide blood samples, CT imaging, and follow-up clinical data would be ideal candidates.
Not a fit: People without fibrosing ILD or those unable to provide blood samples or clinical follow‑up are unlikely to benefit from this work.
Why it matters
Potential benefit: If successful, this could identify people at high risk of rapid decline so they can get earlier treatment and better care planning.
How similar studies have performed: Earlier, smaller proteomic and machine‑learning efforts (including the team's preliminary signature) showed promise but lacked the accuracy and external validation needed for clinical use.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Oldham, Justin M — University of Michigan at Ann Arbor
- Study coordinator: Oldham, Justin M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.